ClinicalTrials.gg
CompletedNCT00541450Updated May 12, 2017Results posted

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

A Phase 3 interventional study of Comparator: sitagliptin phosphate (sitagliptin) and sitagliptin phosphate (+) metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
33rd of 197
492 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
34th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 34th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between the ages of 18 and 78 with type 2 diabetes mellitus
  • Patient has not been on any antihyperglycemic agent (Insulin or oral) in the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Patient has previously been treated with sitagliptin or has previously been in a study using a DPP-4 inhibitor
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
492 participants (actual)

Study arms

  • Experimental
    Sita/Met FDC

    In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks. In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone.

    Drug: Comparator: sitagliptin phosphate (sitagliptin) · Drug: sitagliptin phosphate (+) metformin hydrochloride · Drug: Matching placebo to pioglitazone

  • Active comparator
    Pioglitazone

    In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d. In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks).

    Drug: Comparator: pioglitazone · Drug: Matching placebo to sitagliptin · Drug: Matching Placebo to Sita/Met FDC

Interventions

  • sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period

    Also known as: MK0431, Januvia™

  • Drugsitagliptin phosphate (+) metformin hydrochloride

    Drug pages: Sitagliptin · Metformin

    sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period

    Also known as: MK-0431A, Janumet™

  • pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.

    Also known as: Actos®

  • DrugMatching placebo to pioglitazone

    matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period. Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks.

  • DrugMatching placebo to sitagliptin

    matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.

  • DrugMatching Placebo to Sita/Met FDC

    matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks

    The change in A1C, compared to baseline for the Sita/Met FDC and the pioglitazone groups at Week 40. A1C represents percentage of glycosylated hemoglobin.

    Time frame: Baseline to 40 weeks

  2. Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

    The change in A1C compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. A1c represents percentage of glycosylated hemoglobin.

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Change in 2-hour Postprandial Glucose (PMG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks

    The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the Sita/Met FDC and the pioglitazone groups at Week 40.

    Time frame: Baseline and 40 weeks

  2. Change in 2-hour Postprandial Glucose (PMG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

    The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the participants treated with Sitagliptin or Pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.

    Time frame: Baseline to 12 weeks

  3. Change in Fasting Plasma Glucose (FPG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks

    The change in FPG compared to baseline was measured for the Sita/Met FDC and the pioglitazone groups at Week 40.

    Time frame: Baseline and 40 weeks

  4. Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

    The change in FPG compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.

    Time frame: Baseline to 12 weeks

07

Results

Posted Apr 14, 2011

Participant flow

Phase A
Participant flow — Phase A
MilestoneSita/Met FDCPioglitazone
Started244248
Completed224231
Not completed2017
Withdrew: Adverse event30
Withdrew: Creatinine/crcl -increase in creatinine02
Withdrew: Hyperglycemia01
Withdrew: Lost to follow-up64
Withdrew: Physician decision20
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject77
Phase B
Participant flow — Phase B
MilestoneSita/Met FDCPioglitazone
Started224231
Completed187200
Not completed3731
Withdrew: Adverse event66
Withdrew: Hyperglycemia109
Withdrew: Lost to follow-up64
Withdrew: Physician decision42
Withdrew: Pregnancy01
Withdrew: Protocol violation33
Withdrew: Withdrawal by subject86

Outcome measures

PrimaryChange in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks

The change in A1C, compared to baseline for the Sita/Met FDC and the pioglitazone groups at Week 40. A1C represents percentage of glycosylated hemoglobin.

Time frame:
Baseline to 40 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks
percentage of glycosylated hemoglobinSita/Met FDCPioglitazone
Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks-1.75 (-1.92 to -1.59)-1.38 (-1.55 to -1.21)
Statistical analysis
  • Sita/Met FDC vs Pioglitazone · ANCOVA · p = 0.002For Least Squares Mean, the ANCOVA model included a term for treatment and the baseline value as a covariate.
SecondaryChange in 2-hour Postprandial Glucose (PMG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks

The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the Sita/Met FDC and the pioglitazone groups at Week 40.

Time frame:
Baseline and 40 weeks
Reported as:
Least squares mean · mg/dL
Change in 2-hour Postprandial Glucose (PMG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks
mg/dLSita/Met FDCPioglitazone
Change in 2-hour Postprandial Glucose (PMG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks-90.3 (-99.6 to -81.0)-69.1 (-78.2 to -60.0)
Statistical analysis
  • Sita/Met FDC vs Pioglitazone · ANCOVA · p = 0.001For Least Squares Mean, the ANCOVA model included a term for treatment and the baseline value as a covariate.
PrimaryChange in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

The change in A1C compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. A1c represents percentage of glycosylated hemoglobin.

Time frame:
Baseline to 12 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks
percentage of glycosylated hemoglobinSitagliptin (Phase A)Pioglitazone (Phase A)
Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks-1.03 (-1.18 to -0.88)-0.87 (-1.02 to -0.72)
Statistical analysis
  • Sitagliptin (Phase A) vs Pioglitazone (Phase A) · ANCOVA · Difference in ls means: -0.16 · 95% CI -0.37 to 0.05For Least Squares Mean, the ANCOVA model included a term for treatment and the baseline value as a covariate.
SecondaryChange in 2-hour Postprandial Glucose (PMG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the participants treated with Sitagliptin or Pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.

Time frame:
Baseline to 12 weeks
Reported as:
Least squares mean · mg/dL
Change in 2-hour Postprandial Glucose (PMG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks
mg/dLSitagliptin (Phase A)Pioglitazone (Phase A)
Change in 2-hour Postprandial Glucose (PMG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks-52.8 (-62.4 to -43.3)-50.1 (-59.4 to -40.7)
SecondaryChange in Fasting Plasma Glucose (FPG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks

The change in FPG compared to baseline was measured for the Sita/Met FDC and the pioglitazone groups at Week 40.

Time frame:
Baseline and 40 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose (FPG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks
mg/dLSita/Met FDCPioglitazone
Change in Fasting Plasma Glucose (FPG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks-45.8 (-51.1 to -40.5)-37.6 (-42.8 to -32.4)
Statistical analysis
  • Sita/Met FDC vs Pioglitazone · ANCOVA · p = 0.030For Least Squares Mean, the ANCOVA model included a term for treatment and the baseline value as a covariate.
SecondaryChange in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks

The change in FPG compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.

Time frame:
Baseline to 12 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks
mg/dLSitagliptin (Phase A)Pioglitazone (Phase A)
Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks-26.6 (-31.7 to -21.5)-28.0 (-33.0 to -23.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin (Weeks 0-12)—3/244 (1.2%)7/244 (2.9%)
Pioglitazone (Weeks 0-12)—1/248 (0.4%)15/248 (6%)
Sita/Met FDC (Weeks 0-40)—8/222 (3.6%)20/222 (9%)
Pioglitazone (Weeks 0-40)—3/230 (1.3%)33/230 (14.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSitagliptin (Weeks 0-12)Pioglitazone (Weeks 0-12)Sita/Met FDC (Weeks 0-40)Pioglitazone (Weeks 0-40)
Angina pectorisCardiac disorders0/2440/2481/2220/230
Myocardial infarctionCardiac disorders0/2440/2481/2220/230
Inguinal herniaGastrointestinal disorders0/2440/2481/2220/230
Sudden cardiac deathGeneral disorders0/2440/2481/2220/230
GastroenteritisInfections and infestations1/2440/2481/2220/230
Eye injuryInjury, poisoning and procedural complications0/2440/2481/2220/230
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2440/2481/2220/230
SyncopeNervous system disorders0/2440/2481/2220/230
ProstatitisReproductive system and breast disorders0/2440/2481/2220/230
Atrial fibrillationCardiac disorders0/2440/2480/2221/230
Most frequent other events
Most frequent other events
EventSitagliptin (Weeks 0-12)Pioglitazone (Weeks 0-12)Sita/Met FDC (Weeks 0-40)Pioglitazone (Weeks 0-40)
Oedema peripheralGeneral disorders0/2447/2482/22213/230
NasopharyngitisInfections and infestations4/2446/24812/22212/230
HeadacheNervous system disorders4/2444/2489/22212/230

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sita/Met FDCPioglitazoneTotal
Mean50.5 ± 10.951.7 ± 10.151.1 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Sita/Met FDCPioglitazoneTotal
Female92100192
Male152148300
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Perez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011 Sep;65(9):930-8. doi: 10.1111/j.1742-1241.2011.02749.x. PubMed 21849007 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in Jan 2010, 23 months.

Results were first posted in Apr 2011, 1 year 3 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2007
First posted
Oct 10, 2007
StartActual
Jan 15, 2008
Primary completionActual
Jan 8, 2010
CompletionActual
Jan 16, 2010
Results first posted
Apr 14, 2011
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00541450
Responsible party
Sponsor
First posted
Oct 10, 2007
Start date
Jan 15, 2008
Primary completion
Jan 8, 2010
Completion
Jan 16, 2010
Results posted
Apr 14, 2011
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion